Muscle invasive bladder cancer in the elderly: Treatment and prognosis in a prospective cohort study.

Authors

null

Stephanie Slater

School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom

Stephanie Slater , Thomas Wright , Adam Devall , Sarah Pirrie , Lucinda Billingham , K K Cheng , Maurice Zeegers , Richard Bryan , Nicholas David James

Organizations

School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom, Cancer Research Clinical Trials Unit, School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom, School of Health and Population Sciences, University of Birmingham, Birmingham, United Kingdom, Department of Genetics and Cell Biology, Universiteit Maastricht, Maastricht, Netherlands, Cancer Research UK Clinical Trials Unit, Institute for Cancer Studies, Birmingham, United Kingdom

Research Funding

Other

Background: As the prevalence of bladder cancer increases amongst the elderly, nearly 1 in 3 muscle invasive bladder cancer (MIBC) cases are in patients aged >80 years (Taylor JA, III, Kuchel GA. Nat Clin Pract Urol 2009; 6(3):135-1440). However, radical cystectomy remains as the gold standard treatment for MIBC (Yafi FA, Kassouf W. Can Urol Assoc J 2009; 3(5):409-412). In this study we examined treatment patterns and outcomes patients aged >80 years from a prospective study of bladder cancer. Methods: The Bladder Cancer Prognosis Programme (BCPP) is a 5 year prospective cohort study (2006-2011) with 1191 patients confirmed as having newly-diagnosed bladder cancer. Recruitment took place at 9 urological centres within the West Midlands region, UK. From this cohort we identified 67 patients aged >/=80 years with newly diagnosed MIBC. Study records include overall and disease specific survival, time to disease recurrence and radiotherapy (RT) treatment. Simple descriptive statistics were used to describe the outcomes. Results: This cohort consisted of 46 male and 21 female patients with a median age of 83 (IQR=81, 87; range=80, 94). Only 4 (6%) patients underwent cystectomy and 36 (53%) underwent RT. Median survival data is summarised in the table below. Conclusions: Despite guidelines, practising urologists in the West Midlands region do not offer cystectomy to the vast majority of MIBC patients aged >80 years. Furthermore, in this patient cohort, OS was shorter than BCSS by 10 months, suggesting that quality of life after diagnosis will be far more important than cure rates due to deaths from other causes. Of particular note is that the group receiving RT had longer OS and BCSS than the rest of the cohort. This indicates that RT could be a far more appropriate standard of care in the elderly than surgery, which is clearly of limited applicability in this growing demographic. Clinical trial information: 06/MRE04/65.

Median [95%CI]
Whole
cohort (n=67)
No radiotherapy
(n=31)
Radiotherapy
(n=36)
Overall survival (OS) 14.6 [10.3, 22.0] 11.6 [3.4, 14.6] 19.8 [10.3, 31.1]
Bladder cancer specific
survival (BCSS)
24.3 [14.6, 43.2] 14.6 [9.2, 37.4] 31.1 [17.1, 51.2]
Recurrence free
survival (RFS)
26.1 [23.5, 42.4] 23.5 [8.7, NR] 30.4 [25.5, NR]

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2013 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session B: Prostate, Penile, Urethral, and Testicular Cancer, and Urothelial Carcinoma

Track

Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancer

Sub Track

Urothelial Carcinoma

Clinical Trial Registration Number

06/MRE04/65

Citation

J Clin Oncol 31, 2013 (suppl 6; abstr 275)

DOI

10.1200/jco.2013.31.6_suppl.275

Abstract #

275

Poster Bd #

G4

Abstract Disclosures

Similar Abstracts